Suppr超能文献

无表面活性剂的 BCS 类 IV 药物固体分散体在无定形壳寡糖基质中的应用,可同时提高体外溶解 - 渗透性能。

Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase.

机构信息

School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Engineering Research Center for Efficient Delivery System of TCM, Nanjing 210023, China.

Key Lab of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.

出版信息

Eur J Pharm Sci. 2019 Mar 15;130:147-155. doi: 10.1016/j.ejps.2019.01.031. Epub 2019 Jan 27.

Abstract

Saccharides have been applied as a water-soluble matrix for dispersing hydrophobic drugs homogeneously without the need to use surfactants in amorphous solid dispersions (ASD). Up to now, concomitant permeability improvement of BCS Class IV drug by such matrices have not been much appreciated. Herein, an amorphous chitosan oligosaccharide (COS) was used as matrix to prepare surfactant-free ASD of BCS class IV drug by the ball milling method, with curcumin (CUR) as a model drug. The DSC, XRPD, FTIR and physical stability experiments indicated that CUR was in an amorphous state with high physical stability and exhibited potential interactions with COS in the ASD. Non-sink dissolution in vitro studies showed the maximum dissolution concentration of all CUR-COS ASD (CUR and COS at weight ratios of 1:1, 1:2 and 1:4) reached ranging from 97.85 to 101.21 μg/mL, far above that of pure CUR. The supersaturated concentration remained for at least 24 h under non-sink condition. Caco-2 cell model revealed that, compared to the pure CUR group, the apparent permeability coefficients were increased by 1.72-4.44-fold in all three CUR-COS ASD, which was mainly attributed to opening the tight junctions of Caco-2 cells by COS. The pharmacokinetic study showed that all CUR-COS ASD groups exhibited significant enhancements in AUC, with 1.55-3.01-fold that of pure CUR (p < 0.01). T of CUR was shortened after oral administration of all three ASD. The current study demonstrates the amorphous COS could be used as a promising matrix in ASD for enhancing the oral bioavailability of BCS class IV drug by improving dissolution behavior and membrane permeability.

摘要

糖类已被应用于作为水溶性基质,用于均匀分散亲脂性药物,而无需在无定形固体分散体(ASD)中使用表面活性剂。到目前为止,这种基质对 BCS 类 IV 药物的同时渗透性改善还没有得到太多的重视。本文中,我们使用无定形壳寡糖(COS)作为基质,通过球磨法制备了 BCS 类 IV 药物的无表面活性剂 ASD,以姜黄素(CUR)为模型药物。DSC、XRPD、FTIR 和物理稳定性实验表明,CUR 处于无定形状态,具有较高的物理稳定性,并在 ASD 中与 COS 表现出潜在的相互作用。非溶出度体外研究表明,所有 CUR-COS ASD(CUR 和 COS 重量比为 1:1、1:2 和 1:4)的最大溶解浓度均达到 97.85-101.21μg/mL,远高于纯 CUR。在非溶出条件下,过饱和浓度至少保持 24 小时。Caco-2 细胞模型表明,与纯 CUR 组相比,所有 CUR-COS ASD 的表观渗透系数均增加了 1.72-4.44 倍,这主要归因于 COS 打开了 Caco-2 细胞的紧密连接。药代动力学研究表明,所有 CUR-COS ASD 组的 AUC 均显著增加,与纯 CUR 相比增加了 1.55-3.01 倍(p<0.01)。CUR 的 T 在用所有三种 ASD 口服给药后缩短。本研究表明,无定形 COS 可用作 ASD 中的一种有前途的基质,通过改善溶解行为和膜通透性来提高 BCS 类 IV 药物的口服生物利用度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验